首页> 美国卫生研究院文献>Diabetes Therapy >Effects of the Once-Weekly DPP4 Inhibitor Omarigliptin on Glycemic Control in Patients with Type 2 Diabetes Mellitus on Maintenance Hemodialysis: A 24-Week Open-Label Multicenter Randomized Controlled Study

【2h】

Effects of the Once-Weekly DPP4 Inhibitor Omarigliptin on Glycemic Control in Patients with Type 2 Diabetes Mellitus on Maintenance Hemodialysis: A 24-Week Open-Label Multicenter Randomized Controlled Study

机译：曾经每周DPP4抑制剂Omarigliptin对2型糖尿病患者血糖对血液透析性的血糖控制的影响：24周开放标签多中心随机对照研究

代理获取

本网站仅为用户提供外文OA文献查询和代理获取服务，本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文，但由于OA文献来源多样且变更频繁，仍可能出现获取不到、文献不完整或与标题不符等情况，如果获取不到我们将提供退款服务。请知悉。

页面导航

摘要
著录项
相似文献
相关主题

摘要

The online version contains supplementary material available at 10.1007/s13300-020-00991-y.

机译：在线版本包含10.1007 / S13300-020-00991-Y可用的补充材料。

著录项

期刊名称 Diabetes Therapy
作者
Yuta Yoshizawa; Michihiro Hosojima; Hideyuki Kabasawa; Naohito Tanabe; Daisuke Ugamura; Yutaka Koda; Hisaki Shimada; Tetsuya Takasawa; Takahito Ito; Tadahiro Kitamura; Masaki Kobayashi; Yoshiki Suzuki; Ichiei Narita; Akihiko Saito;
展开▼
作者单位

展开▼
年(卷),期 2021(12),3
年度 2021
页码 655–667
总页数 13
原文格式 PDF
正文语种
中图分类基础医学 ;
关键词
Linagliptin; Hemodialysis; Once-weekly dipeptidase 4 inhibitor; Omarigliptin; Type 2 diabetes mellitus;

机译：Linagliptin;血液透析;每周一次二肽酶4抑制剂;omarigliptin;2型糖尿病;

相似文献

外文文献
中文文献
专利

1. Effects of the Once-Weekly DPP4 Inhibitor Omarigliptin on Glycemic Control in Patients with Type?2 Diabetes Mellitus on Maintenance Hemodialysis: A 24-Week Open-Label, Multicenter Randomized Controlled Study [J] . Yuta Yoshizawa, Michihiro Hosojima, Hideyuki Kabasawa, Diabetes therapy . 2021 ,第3期

机译：曾经每周DPP4抑制剂Omarigliptin对患者血液透析患者血糖对照的影响：24周的开放标签，多中心随机对照研究
2. A randomized, placebo-controlled study of the cardiovascular safety of the once-weekly DPP-4 inhibitor omarigliptin in patients with type 2 diabetes mellitus [J] . Ira Gantz, Menghui Chen, Shailaja Suryawanshi, Cardiovascular Diabetology . 2017 ,第1期

机译：每周一次的DPP-4抑制剂奥格列汀对2型糖尿病患者的心血管安全性的随机安慰剂对照研究
3. A randomized, placebo-controlled clinical trial evaluating the safety and efficacy of the once-weekly DPP-4 inhibitor omarigliptin in patients with type 2 diabetes mellitus inadequately controlled by glimepiride and metformin [J] . Seung-Hwan Lee, Ira Gantz, Elizabeth Round, BMC Endocrine Disorders . 2017 ,第1期

机译：一项随机，安慰剂对照的临床试验，评估了每周一次的DPP-4抑制剂奥格列汀在格列美脲和二甲双胍控制不足的2型糖尿病患者中的安全性和有效性
4. A series of open-label studies comparing various formulations of orally administeredinsulin (Oralin) in patients with Type -1 Diabetes Mellitus (DM) [C] . Jaime Guevara-Aguirre, Marco Guevara, Jeannette Saavedra Annual meeting exposition of the Controlled Release Society . 2005

机译：一系列开放标签研究比较了-1型糖尿病（DM）患者口服胰岛素（Oralin）的各种配方
5. A 4-month randomized controlled clinical trial of adjuvant Exenatide or Pramlintide versus insulin alone in pediatric type 1 diabetes mellitus: Effect on glycemic control. [D] . Withycombe, Sarah Elizabeth. 2010

机译：儿科1型糖尿病患者中艾塞那肽或普兰林肽与单独使用胰岛素的4个月随机对照临床试验：对血糖控制的影响。
6. A randomized placebo-controlled study of the cardiovascular safety of the once-weekly DPP-4 inhibitor omarigliptin in patients with type 2 diabetes mellitus [O] . Ira Gantz, Menghui Chen, Shailaja Suryawanshi, 2017

机译：每周一次的DPP-4抑制剂奥格列汀对2型糖尿病患者的心血管安全性的随机安慰剂对照研究
7. Effects of the Once-Weekly DPP4 Inhibitor Omarigliptin on Glycemic Control in Patients with Type 2 Diabetes Mellitus on Maintenance Hemodialysis: A 24-Week Open-Label, Multicenter Randomized Controlled Study [O] . Yuta Yoshizawa, Michihiro Hosojima, Hideyuki Kabasawa, 2021

机译：曾经每周DPP4抑制剂Omarigliptin对2型糖尿病患者血糖对血液透析性的血糖控制的影响：24周开放标签，多中心随机对照研究

Effects of the Once-Weekly DPP4 Inhibitor Omarigliptin on Glycemic Control in Patients with Type 2 Diabetes Mellitus on Maintenance Hemodialysis: A 24-Week Open-Label Multicenter Randomized Controlled Study

摘要

著录项

相似文献

相关主题

期刊订阅